Table 2.
Baseline characteristics of patients treated with first- or second-line abiraterone acetate (AAP) or enzalutamide (ENZ) in mCRPC.
| Characteristics | 1st line | 2nd line | ||
|---|---|---|---|---|
| AAP n = 87 | ENZ n= 88 | AAP n = 29 | ENZ n = 47 | |
| Median age at ARPI initiation, years | 78 | 73 | 74 | 73 |
| ECOG, n (%) | ||||
| 0 | 49 (56) | 67 (76) | 11 (38) | 34 (72) |
| 1 | 29 (33) | 14 (16) | 13 (45) | 11 (23) |
| > 2 | 8 (9) | 5 (6) | 4 (14) | 2 (4) |
| Gleason Score, n (%) | ||||
| 7 | 13 (15) | 16 (18) | 7 (24) | 9 (19) |
| 8 | 9 (10) | 6 (7) | 6 (21) | 8 (17) |
| ≥9 | 32 (37) | 34 (39) | 10 (34) | 19 (40) |
| Co-morbidities, n (%) | ||||
| Hypertension | 52 (60) | 52 (59) | 15 (52) | 30 (64) |
| Hypercholesterolaemia | 34 (39) | 37 (42) | 14 (48) | 22 (47) |
| GORD or peptic ulcer disease | 22 (25) | 18 (20) | 6 (21) | 11 (23) |
| IHD | 18 (21) | 17 (19) | 8 (28) | 8 (17) |
| Diabetes | 13 (15) | 18 (20) | 8 (28) | 8 (17) |
| Atrial fibrillation and other arrhythmia | 21(24) | 13 (15) | 3 (10) | 7 (15) |
| Depression or anxiety | 13 (15) | 9 (10) | 5 (17) | 6 (13) |
| Cognitive impairment | 8 (9) | 1 (1) | 2 (7) | 1 (2) |
| Stroke | 7 (8) | 4 (5) | 3(10) | 2(4) |
| Heart failure | 7 (8) | 8 (9) | 2 (7) | 4 (9) |
| Falls | 4 (5) | 1 (1) | 0 (0) | 1 (2) |
| Parkinson’s disease | 4 (5) | 0 (0) | 0 (0) | 1 (2) |
| Traumatic brain injury | 3 (3) | 0 (0) | 1 (3) | 1 (2) |
| Seizures | 2 (2) | 0 (0) | 0 (0) | 0 (0) |
| CCI, median | 10 | 9 | 10 | 9 |
| Conmeds, median (range) | 4 (0-19) | 4 (0-18) | 6 (0-15) | 5 (0-15) |
Comorbidities with potential to interact with respective androgen receptor pathway inhibitors (ARPI) are shaded in orange.
CCI, Charlson co-morbidity index; conmeds, concomitant medications; ECOG, Eastern Cooperative Oncology Group performance status; GORD, gastro-oesophageal reflux disease; IHD, ischaemic heart disease.